Welnox, a Martin Dow Group company, has entered into a licensing partnership with Procter & Gamble (P&G) for Vicks VapoRub. The company expects the product to reach pharmacies across Pakistan in the coming weeks.
Welnox announced the agreement in Karachi on September 15, 2026, as it moves to expand its consumer healthcare portfolio. The partnership brings the longstanding cough and cold care brand into the company’s plans for growth in Pakistan.
Read More: Unilever Says It Is Already Ahead of Target After P&G’s Exit
The company said the agreement supports Martin Dow’s commitment to improving access to high-quality, reliable healthcare solutions for millions of consumers nationwide.
Anwar Zaman, CEO, Welnox, said, “Vicks VapoRub is an iconic brand with enduring equity, and a natural fit with our vision to build a strong, consumer-centric healthcare portfolio. We see significant opportunity to build on its strong foundation and unlock new avenues of growth in Pakistan.”
The announcement identifies pharmacies as the retail channel for the upcoming rollout. However, it does not specify an exact availability date, retail prices or pack sizes. It also does not disclose the financial terms or duration of the licensing agreement.
Welnox expands consumer health portfolio
The agreement follows Martin Dow’s establishment of Welnox Limited in 2024 as part of its consumer health portfolio. The group describes Welnox as its consumer health business unit, focused on accessible, science-backed wellness solutions.
That focus places everyday healthcare products at the centre of Welnox’s business. Zaman’s remarks indicate that the company views Vicks VapoRub as a brand around which it can develop further growth in Pakistan.
Martin Dow’s corporate history also shows previous agreements involving international pharmaceutical businesses. In 2010, it acquired Roche’s facility in Pakistan, alongside acquisitions and brand licensing involving Roche’s global product lines.
The group later acquired Merck Germany’s shareholding in Merck Pakistan in 2016, along with two manufacturing facilities. These transactions provide background to Martin Dow’s experience with international healthcare partnerships, although the Welnox announcement concerns a licensing arrangement specifically for Vicks VapoRub.
A brand with more than 125 years of history
Welnox described Vicks as a familiar part of family care routines across generations, with more than 125 years of heritage.
According to the announcement, Vicks VapoRub helps relieve common cold symptoms, including nasal congestion, cough, headache, body ache and discomfort associated with breathing.
Read More: Pakistani Doctors Prescribe Over Twice WHO-Recommended Medicines
The brand’s official history traces its origins to 1894, when pharmacist Lunsford Richardson developed remedies in Greensboro, North Carolina. His work eventually produced a family of 21 remedies sold under the Vicks name.
For Pakistani consumers, the immediate development is the planned pharmacy rollout under Welnox’s partnership with P&G. The company has set a timeframe of the coming weeks but has yet to announce a specific launch day.
